Publication Highlight: Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness in Chronic Kidney Disease
Publication Highlight: Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness
IMNO 2024: Imaging Network Ontario Symposium
The Imaging Network Ontario (ImNO) hosts an annual symposium that promotes collaborations, broadcasts career opportunities, informs trainees on diverse imaging applications and fosters a greater understanding of the commercialization process. The symposium features world-renowned keynote speakers and sessions that bring together our trainees with imaging scientists, clinicians and patient groups, and industry representatives. Scintica will be there at Table #1! Make sure to stop by and say hi!
When does the Meeting Take Place?
Tuesday, March 19 – Wednesday, March 20
Where is this year’s IMNO 2024 Annual Meeting?
Hilton Mississauga Meadowvale
Mississauga, ON
Read more about Science!
Application Note: Bioprinting 3D Multi-cellular Cartilage Spheroids Using Laser-Assisted Technology
Application Note: Bioprinting 3D Multi-cellular Cartilage Spheroids Using Laser-Assisted Technology View Paper Here
Publication Highlight: Single High-Dose Erythropoietin Disrupts Bone Homeostasis via Osteoclastogenic Pathways
Publication Highlight: Single High-Dose Erythropoietin Disrupts Bone Homeostasis via Osteoclastogenic Pathways View Paper
Publication Highlight: Long-Term Optical Imaging Reveals Bone Marrow Clearance and Extramedullary Escape in BCMA CAR-NK Therapy
Publication Highlight: Long-Term Optical Imaging Reveals Bone Marrow Clearance and Extramedullary Escape in
Publication Highlight: Overexpression of IL-32γ inhibits skin cancer formation through suppression of NF-κB and its downstream factors
Publication Highlight: Overexpression of IL-32γ inhibits skin cancer formation through suppression of NF-κB
Publication Highlight: The role of phosphodiesterase 5 inhibitors in attenuating obesity-induced metabolic disorders
Publication Highlight: The role of phosphodiesterase 5 inhibitors in attenuating obesity-induced metabolic disorders